Sorafenib: new indication. For some patients with liver cancer
- PMID: 19585718
Item in Clipboard
Sorafenib: new indication. For some patients with liver cancer
Prescrire Int.
2009 Apr.
Abstract
In a trial involving patients with advanced-stage liver cancer but unimpaired hepatic function, sorafenib increased the median survival time by about 3 months in half of patients, but provoked frequent adverse effects.
Similar articles
-
Sorafenib for the treatment of unresectable hepatocellular carcinoma.Oncologist. 2009 Jan;14(1):95-100. doi: 10.1634/theoncologist.2008-0185. Epub 2009 Jan 14. Oncologist. 2009. PMID: 19144678 Review.
-
[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].Gastroenterol Clin Biol. 2008 Jan;32(1 Pt. 1):3-7. doi: 10.1016/j.gcb.2007.11.001. Epub 2008 Mar 4. Gastroenterol Clin Biol. 2008. PMID: 18341970 French. No abstract available.
-
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.Expert Rev Anticancer Ther. 2009 Jun;9(6):739-45. doi: 10.1586/era.09.41. Expert Rev Anticancer Ther. 2009. PMID: 19496710
-
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.J Clin Gastroenterol. 2009 May-Jun;43(5):489-95. doi: 10.1097/MCG.0b013e31818ddfc6. J Clin Gastroenterol. 2009. PMID: 19247201
-
Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.Oncology. 2010 Jul;78 Suppl 1:154-66. doi: 10.1159/000315245. Epub 2010 Jul 8. Oncology. 2010. PMID: 20616599 Review.
MeSH terms
Substances
LinkOut - more resources
Medical